

DAFTAR PUSTAKA

1. Global Cancer Observatory, International Agency for Research on Cancer <http://www.globocan.iacr.com2021>.
2. Anwar Jusuf AW, Aziza G Icksan, Elisna Syahrudin, Juniarti, Sutjahjo Endardjo. Kanker Paru Jenis Karsinoma Bukan Sel Kecil : Pedoman Diagnosis dan Penatalaksanaan di Indonesia: Perhimpunan Dokter Paru Indonesia; 2015.
3. Syahrudin E. 2010. Efusi pleura ganas dan sistem TNM untuk staging kanker paru jenis karsinoma bukan sel kecil (KPKBSK) Versi 7, UICC 2009. *J Respir Indo*; 30(3):132-133.
4. Supartono dan Suryanto A. 2012. Faktor-faktor yang mempengaruhi ketahanan hidup satu tahun penderita kanker paru stadium lanjut di RSUP dr. Kariadi Semarang. *Medica Hospitalia*; 1(1):25-31.
5. Surjanto E, Sutanto YS, Aphridasari J, Leonardo. 2014. Penyebab efusi pleura pada pasien rawat inap di rumah sakit. *J Respir Indo*; 34:102-8.)
6. Syahrudin E, Avissena DP, Nirwan A. A retrospective study : Clinical and diagnostic characteristic in advanced stage of lung cancer patients with pleural effusion in persahabatan hospital 2004 2007. *J. Respir Indo* 2010;30:146-51.
7. Bielsa S, Salud A, Martinez M, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. *Eur J Intern Med* 2008; 19:334–9.
8. Syahrudin E, dkk. Kanker Paru : Pedoman Penstagingan dan Pengevaluasian Hasil Terapi di Indonesia Edisi 2019. Perhimpunan Dokter Paru Indonesia 2019.
9. Komite Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran : Kanker Paru. Kementerian Kesehatan Republik Indonesia 2017.
10. Anwar Jusuf AW, Aziza G Icksan, Elisna Syahrudin, Juniarti, Sutjahjo Endardjo. Kanker Paru Jenis Karsinoma Bukan Sel Kecil : Pedoman Diagnosis dan Penatalaksanaan di Indonesia: Perhimpunan Dokter Paru Indonesia; 2015.
11. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. *Ann Glob Heal*. 2019;85(1):1-16. doi:10.5334/aogh.2419.
12. National T, Cancer C. Non-Small Cell Lung. Cancer. Published online 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
13. Rasmin M, Jusuf A, Yunus F, et al. Buku Ajar Pulmonologi Dan Kedokteran Respirasi. Buku 2. UI Publishing; 2018.
14. Keputusan menteri kesehatan republik indonesia nomor 1022/menkes/xi/2008 tentang pedoman pengendalian penyakit paru obstruktif kronik. In: Indonesia KK, editor. 2008.
15. Schabath MB, Haura EB. Epidemiology of non-small cell lung neoplasms. *MODERN THORACIC ONCOLOGY: Volume 2: Trachea, Lung, and Pleura: World Scientific*; 2018. p. 61-6.
16. Wu L, Wen X, Wang X, Wang C, Sun X, Wang K, et al. Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging. *Theranostics*. 2018;8(2):563.

17. Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer : Reference Chart and Diagrams. *The Oncologist* 2018 ;23 :1-5.
18. Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, et al. *Fishman's pulmonary diseases and disorders*. 4th ed. New York: McGraw Hill Medical, 2008.
19. Rasmin M, Jusuf A, Amin M, Taufik, Nawas MA. *Buku Ajar Pulmonologi dan Kedokteran Respirasi Buku 1*. Jakarta : Kolegium Pulmonologi dan Kedokteran Respirasi. 2017;92-9.
20. Netter FH. *The ciba collection of medical illustrations vol. 7 respiratory system* 2 nd ed. USA : Ciba. 1980 ; 32-3.
21. Lechner JA. *Respiratory: An Integrated Approach to Disease*. McGraw-Hill Professional: New York. 2011. Light RW. *Pleural Disease*, sixth edition. USA : Vanderbilt University, Nashville. 2013 ;12-4, 140-50, 247-48, 287-88.
22. Auliya Husnul, Roza Kurniati. *Diagnosis and Management of Ganasnt Pleural Effusion : A Narrative Literature Review*. *Bioscientia Medicina: Journal of Biomedicine & Translational Research*. doi.org/10.37275/bsm.v6112.624. eISSN (online): 2598-0580. www.bioscm.
23. Jen Peng M, San Wang N. *Anatomy of the Pleura*. In : Bouros D, Ed. *Pleural Disease*. New York. 2004.
24. Light RW. *Pleural Disease*, sixth edition. USA : Vanderbilt University, Nashville. 2013 ;12-4, 140-50, 247-48, 287-88.
25. C, Yao. M, Nicholas W. *The role of VEGF in the diagnosis and treatment of ganasnt pleural effusion in patients with non-small cell lung cancer (Review)*. *Molecular medicine reports* 17 2018. P: 8019-8030.
26. Lechner JA. *Respiratory: An Integrated Approach to Disease*. McGraw-Hill Professional: New York. 2011.
27. Wande I. *Analisis cairan pleura*. In: Wande I, editor. *Buku panduan interpretasi analisis cairan pleura*. 1st ed. Denpasar: Bagian Patologi Klinik FK Universitas Udayana; 2016. p. 1-15.
28. Broaddus V. Courtney, Robert J. Murray and Nadel's *Textbook of Respiratory Medicine* 6th edition. Chapter 8. *Pleural effusion*. 2016. English.
29. Afien Mohammad Mukti. *Uji Diagnostik Cancer Rasio dan Rasio Sel Darah Merah Cairan Pleura/Adenosine Deaminase Cairan Pleura Untuk Mengidentifikasi Efusi Pleura Ganas*. 2021. Surakarta.
30. Nugroho Bimo. *Kadar Lactate Dehydrogenase Dan Glukosa Cairan Pleura Sebagai Prediktor Respon Pleurodesis di Rumah Sakit DR Moewardi*. 2021. Surakarta.
31. Reciana Maria Setialaini. *Uji Diagnostik Cancer Rasio Plus dan Rasio Lactate Dehydrogenase Serum/LactatLimfosit Cairan Pleura Untuk Identifikasi Efusi Pleura Ganas*. 2022. Surakarta.
32. Movahed G, Rastegari-pouyani M, Mohammadi M, Mansouri K. *Cancer cells change their glucose metabolism to overcome increased ROS: one step from cancer cell to cancer stem cell?* *Biomed Pharmacother*. 2019;112:1-15.
33. RodríguezPanadero F, LópezMejías J: *Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis*. *Am Rev Respir Dis* 1989;139:663–667.
34. Taryle DA, Good JT Jr, Sahn SA. *Acid generation by pleural fluid: possible role in the determination of pleural fluid pH*. *J Lab Clin Med* 1979; 93:1041-

- 6.
35. Verma akash, Phua Chee kiang, et..al. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.Singapore.2015.
36. Van Veelen A, Abtahi S, Souverein P, Driessen JHM, Klungel OH, Dingemans AMC, et al. Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune chec.
37. Putri A, Pratiwi SE, Musawaris RF. Characteristics of Lung Cancer Patients at Dr. Soedarso Hospital Pontianak from 2017 to 2019. *Indones J Cancer* [Internet]. 2023 Jun 21 [cited 2024 May 27];17(2):101–4. Available from: <https://www.indonesianjournalofcance>.
38. Sivabalan Logawathi S, Causa Trisna Mariedina. Characteristics of Lung Cancer Patients in Haji Adam Malik General Hospital Medan in 2016-2018. *J Endocrinol Trop Med Infect Dis*. 2020;
39. Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, Ahn JS, et al. Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry. *Tuberc Respir Dis (Seoul)* [Internet]. 2019 [cited 2024.
40. Ramirez RA, Surinach A, Cockrum P. Patient characteristics and outcomes associated with small cell lung cancer by treatment status in a U.S. Medicare population. https://doi.org/101200/JCO20224016_suppl.e20614 [Internet]. 2022 Jun 2 [cited 2024 May 28];40.
41. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. *Respirology* [Internet]. 2015 May 1 [cited 2024 May 29];20(4):654–9. Available from: <https://onlinelibrary-wiley-com.ez>.
42. Kasapoglu US, Arınç S, Gungor S, Irmak I, Guney P, Aksoy F, et al. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. *Clin Respir J* [Internet]. 2016 Nov 1 [cited 2024 May 29];10(6):791–9. Avai.
43. Ratna Andriani author. Karakteristik, angka tahan hidup dan faktor prognostik pasien kanker paru jenis karsinoma sel kecil = Characteristics, survival rate and prognostic factors of small cell lung cancer patients [Internet]. 2014 [cited 2024 May 28].
44. Yovi Indra, Dewi Anggaraini, Suci Ammalia.Hubungan Karakteristik dan Etiologi Efusi Pleura di RSUD Arifin Achmad Pekanbaru. *J.Respir Indo Vol* 37 No 2 April 2017
45. Fachrurozi Muhammad S, Hasrayati Agustina, Iceu Dimas Kulsum. Profil Klinis, GambaranMakroskopis dan Mikroskopis Cairan Efusi Pleura Pada Pasien Rawat Inap Di Departemen Penyakit Dalam RSUP DR Hasan Sadikin Bandung Periode Janurai 2016-Desember 2018. *Indonesia Journal Chest*. Vol7, No 1 jan-Juni 2020
46. Xu Ke, Xiaodi Wu, Lu Chen, etc. Risk Factors for Symptomatic Malignant Pleural Effusion Recurrence in Patients with Actionable Mutations in Advance Lung Carcinoma. *Transl Lung Cancer Res*.2023 Sep. doi: 10.21037/tclr-23-151
47. Conrado Fernando Abrao, Igor Renato Louro, etc. Prognostic Factor of Recurrence of Malignanct PLeural Effusion :What Is The Role of Neopasia Prognstic. *Journal of Thoracic Disease*.2020:12 (3):813-822. doi.org/10.2103/jtd.2020.01.13

- 48 Xie LX, Wang XG, You WJ, Ma X Bin, Wang YG, Liu TT, et al. Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy. *Thorac Cancer*. 2019 Jun 1;10(6):1412–8.
49. Saha K, Maikap MK, Maji A, Moitra M, Jash D. Demographic, clinical, biochemical, radiological and etiological characteristics of malignant pleural effusions from Eastern India. *Indian J Cancer* [Internet]. 2017 Jan 1 [cited 2024 May 29];54(1):257–61
- 50 Keidan N, Aujayeb A. Small Cell Lung Cancer and Pleural Effusion: An Analysis from a District General Hospital. *Pulm Ther* 2023 93 [Internet]. 2023 Jun 6 [cited 2024 May 29];9(3):359–65. Available from: <https://link.springer.com/article/10.1007/s41030-023->
- 51 Eleftheriou D, Kallianos A, Adrianopoulos A, Rapti A. AB 28. Evaluation of pleural effusion at first diagnosis of lung cancer. *J Thorac Dis* [Internet]. 2012 [cited 2024 May 29];4(Suppl 1). Available from: <https://jtd.amegroups.org/article/view/698>.
- 52 Lee J, Lee YH, Seo H, Do YW, Lee DH, Lee SY, et al. Characteristics and survival impact of polymorphonuclear leucocyte-predominant malignant pleural effusions secondary to lung cancer. *Clin Respir J* [Internet]. 2020 Aug 1 [cited 2024 May 28];14(8):772–9. .
- 53 Bechara RI, Bonta D, Webb N, Allen S. Impact of Pleural Effusions Volume and Cytology on Outcomes in Cancer Patients. 2021 May;A4757–A4757.
- 54 Zamboni MM, da Silva CT, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. *BMC Pulm Med* [Internet]. 2015 Mar 28 [cited 2024 May 29];15(1). Available from: <https://pmc/articles/PMC4379612/>.
- 55 Yoshimura A, Yamada T, Tsuji T, Hamashima R, Shiotsu S, Yuba T, et al. Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. *Thorac Cancer* [Internet]. 2019 Mar 1 [cited 2024 May 29];10(3):557–63.
- 56 Bokan D, Zaric B, Kovacevic T, Stojanovic G, Djekic Malbasa J. Real-world data on survival outcomes and characteristics of lung cancer patients in northern serbia. https://doi.org/10.1200/JCO20234116_suppl.e22528 [Internet]. 2023 May 31 [cited 2024 May 28].
- 57 He S, Li H, Cao M, Sun D, Yang F, Yan X, et al. Survival of 7, 311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. *Transl Lung Cancer Res* [Internet]. 2022 Aug 1 [cited 2024 May 28];1.
58. Shi Y, Chen W, Li C, Qi S, Zhou X, Zhang Y, et al. Clinicopathological characteristics and prediction of cancer-specific survival in large cell lung cancer: a population-based study. *J Thorac Dis* [Internet]. 2020 May 1 [cited 2024 May 28];12(5):2261–9. Av.
- 59 Navasakulpong A, Kaenmuang P. Survival and prognostic factors in NSCLC patients with malignant pleural effusion. *Eur Respir J* [Internet]. 2022 Sep 4 [cited 2024 May 28];60(suppl 66):425. Available from: https://erj.ersjournals.com/content/60/suppl_66/425.
- 60 Montero-Arias F, Cartin-Ceba R, Rojas-Solano J, Ugalde-Gamboa L, Ramos-Esquivel A. Pleural Effusion Size as Prognostic Marker in Patients With Malignant Pleural Effusion. <http://dx.doi.org/10.1177/2373997515600657> [Internet]. 2015 Aug 17 [cited 2024 May 29].

- 61 Deniz Sami, Zubeyde Gulce, etc. May Biochemical Variable and Pleural Fluid Cell Count be Used in The Benign-Malign Differentiation of Pleural Effusions Associated with lung cancer. *Bezmillem Science Publish*. 2019. doi 10.14235/bas.galenos.2018.2130
- 62 Pantazopoulos I. Pleural fluid glucose: A predictor of unsuccessful pleurodesis in a preselected cohort of patients with malignant pleural effusion. [cited 2024 May 31]; Available from: www.jbuon.com.
- 63 Abrao FC, de Abreu IRLB, Fogarolli M, Caxeiro G, Bezerra CBS, de Cerqueira Cesar FP, et al. Prognostic Factors of 30-Day Mortality After Palliative Procedures in Patients with Malignant Pleural Effusion. *Ann Surg Oncol*. 2015;

